TITLE

Another Study Implicates Avandia

AUTHOR(S)
Elliott, William T.
PUB. DATE
February 2008
SOURCE
Travel Medicine Advisor;Feb2008, Vol. 18 Issue 2, p1
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article reports on a study in Ontario implicating the rosiglitazone Avandia from GlaxoSmithKline with an increased risk of heart failure, cardiovascular events and mortality when compared to other oral hypoglycemic agents. It notes that the primary outcome was emergency visit or hospitalization for congestive heart failure (CHF). The study also evaluated thiazolidinediones. It cites that the adverse effects were found in patients who took the drug as a single agent or in combination with other hypoglycemic agents.
ACCESSION #
30001714

 

Related Articles

  • Another Study Implicates Avandia. Elliott, William T. // Clinical Oncology Alert;Feb2008 Pharmacology Watch, Vol. 24, p1 

    The article reports on a study which linked the rosiglitazone drug Avandia from GlaxoSmithkline with an increased risk of heart failure, cardiovascular events and mortality as compared to other oral hypoglycemic agents based on data from health care databases Ontario. Primary outcome in older...

  • Another Study Implicates Avandia. Elliott, William T. // Neurology Alert;Feb2008, Vol. 26 Issue 6, p1 

    The article reports on a study which found that rosiglitazone from GlaxoSmithKline is associated with an increased risk of heart failure, cardiovascular events and mortality. The patient population in the study was about 160,000 older people with type 2 diabetes. The initial outcome was...

  • Sulfonylureas show unfavourable risk profiles.  // Reactions Weekly;1/9/2010 Part 1 of 2, Issue 1283, p6 

    This article discusses research being done on the risk profiles of sulfonylureas. It references a study by I. Tzoulaki et al., published in the "British Medical Journal" in 2010. The study used the UK General Practice Research Database to gather information on diabetics who received oral...

  • Another Study Implicates Avandia. Elliott, William T. // Primary Care Reports;Feb2008, Vol. 14 Issue 2, p1 

    This article discusses a study implicating rosiglitazone or Avandia with an increased risk of heart failure, cardiovascular events and mortality when compared to other oral hypoglycemic agents. The research was a nested case-control analysis of a retrospective cohort study using health care...

  • Diastolic dysfunction also predicts mortality.  // Geriatrics;Mar2003, Vol. 58 Issue 3, p16 

    Cites the findings of the research conducted by the Mayo Clinic indicating that more than one-quarter of adults over age 45 in the U.S. have diastolic dysfunction and are at increased risk of mortality. Percentage of study participants with congestive heart failure (CHF); Mortality risk of...

  • Pioglitazone swells risk of oedema.  // Reactions Weekly;10/6/2007, Issue 1172, p5 

    The article reports on the findings of a study which examined the association between pioglitazone and increased risk of oedema and congestive heart failure. As a result of this association, glitazones cannot be prescribed in Europe. Meta-analyses has been conducted by researchers to assess the...

  • Avandia, Risk of Congestive Heart Failure Significant Safety Risk.  // Internal Medicine Alert;7/15/2007, Vol. 29 Issue 13, p1 

    The article reports on the risk of congestive heart failure associated with the use of rosiglitazone from GlaxoSmithKline.

  • Dronedarone increases mortality in heart failure patients but might decrease mortality in patients with atrial fibrillation. Margulescu, Andrei Dumitru // Maedica - a Journal of Clinical Medicine;2008, Vol. 3 Issue 2, p142 

    The article discusses impact of dronedarone on the mortality of heart failure patients and patients with atrial fibrillation. Research revealed that dronedarone increases mortality of heart failure patients; however, decreases mortality to patients with atrial fibrillation. Heart failure is...

  • Cibenzoline.  // Reactions Weekly;9/25/2010, Issue 1320, p17 

    The article describes a case of fatal congestive heart failure in a 46-year-old man who received cibenzoline for paroxysmal atrial fibrillation.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics